We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Micro-Mechanical Blood Clot Testing Using Smartphones

By LabMedica International staff writers
Posted on 23 Feb 2022
Print article
Image: A new blood-clotting test that uses only a single drop of blood and a smartphone with a plastic attachment that holds a tiny cup beneath the phone’s camera (Photo courtesy of Mark Stone/University of Washington)
Image: A new blood-clotting test that uses only a single drop of blood and a smartphone with a plastic attachment that holds a tiny cup beneath the phone’s camera (Photo courtesy of Mark Stone/University of Washington)

Researchers have developed a new blood-clotting test that uses only a single drop of blood and a smartphone vibration motor and camera.

The human body responds to injury with bleeding, followed by clot formation and eventually lysis. This carefully maintained homeostasis minimizes the risks of hemorrhage and inappropriate clotting like ischemic stroke, myocardial infarction or pulmonary embolus.

Frequent prothrombin time (PT) and international normalized ratio (INR) testing is critical for millions of people on lifelong anticoagulation with warfarin. Currently, testing is performed in hospital laboratories or with expensive point-of-care devices limiting the ability to test frequently and affordably.

Medical Scientists at the University of Washington (Seattle, WA, USA) have described a proof-of-concept system that uses the vibration motor and camera on existing smartphones to perform PT/INR testing. Smartphones are increasingly becoming ubiquitous in resource-constrained environments and developing countries both in rural and urban settings. Vibration motors and cameras have been an integral part of smartphones for more than a decade. Repurposing these smartphone sensors for PT/INR testing could enable a more affordable blood clot testing tool.

In the new system a drop of blood is added to a small silicone cup, which contains a minute copper particle and a chemical that starts the blood-clotting process. Then the phone's vibration motor shakes the cup while the camera monitors the movement of the particle, which slows down and then stops moving as the clot forms. To calculate PT and INR, the phone collects two time stamps: first when the user inserts the blood and second when the particle stops moving.

The investigators designed a custom Android application on a Samsung Galaxy S9 to perform measurements. The vibration motor on the Samsung Galaxy S9 has a resonant frequency of 159 Hz. The motor was set to vibrate continuously while the camera recorded the clotting process. The camera had an ISO of 320, 1/60 shutter speed, 5500 K white balance and captured frames at the maximum frame rate. The scientists showed that this method falls within the accuracy range of the standard instruments of the field.

The team tested this method on three different types of blood samples. As a proof of concept, the team started with plasma, a component of blood that is transparent and therefore easier to test. They then tested plasma from 140 anonymized patients and also examined plasma from 79 patients with known blood-clotting issues. For both these conditions, the test had results that were similar to commercially available tests. To mimic what a patient at home would experience, the team then tested whole blood from 80 anonymized patients. This test also yielded results that were in the accuracy range of commercial tests.

Shyamnath Gollakota, PhD, an Associate Professor and senior author of the study, said, “Almost every smartphone from the past decade has a vibration motor and a camera. This means that almost everyone who has a phone can use this. All you need is a simple plastic attachment, no additional electronics of any kind. This is the best of all worlds; it's basically the holy grail of PT/INR testing. It makes it frugal and accessible to millions of people, even where resources are very limited.”

The authors concluded that given the ubiquity of smartphones in the global setting, this proof-of-concept technology may provide affordable and effective PT and INR testing in low-resource environments. The study was published on February 11, 2022 in the journal Nature Communications.

Related Links:
University of Washington 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.